PDS Biotechnology Corporation

NASDAQ:PDSB

Biotechnology

Healthcare
$0.92 +1.21%

+$0.01 today

Market cap
$51.58M
Beta
1.56
P/E (TTM)
-1.5
EPS (TTM)
-$0.60
52W Low $0.51High $1.67

Volume 5.25M

Average 1.04M

PDSB Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

PDS Biotechnology CorporationNASDAQ: PDSB

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables dips below year-ago levels

Q1 FY2026 accounts payables of $75.9K fell 93.5% year over year, behind the +301.2% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -93.5% toward the trailing-twelve-month pace of +301.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$75.9K+104.7% QoQ
Last fiscal yearDec 2025
$1.89M+135.7% YoY
LTMMar 2026
$791.06K+301.2% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-93.5%——
1 year+135.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
1.89M USD
Year-over-year change
+135.7%

Accounts Payables vs competitors

How PDSB compares with its peers on the latest reported figures

  • PDSB's LTM Mar 2026 accounts payables of $791.06K is the 5th largest of the 6 companies compared; the peer median is $938K.
  • Its year-over-year change of +301.2% is the highest of 6, against a peer median of -7.3%.
PDSB Competitors Peer median
Accounts Payables for PDSB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANVSAnnovis Bio, Inc.LTM Mar 2026$3.91M +242.7%-55.7%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026$2.41M -126.0%——
INMBINmune Bio, Inc.LTM Mar 2026$1.9M -7.3%+9.8%—
XLOXilio Therapeutics, Inc.LTM Mar 2026$938K -175.6%-32.1%1.8%
PDSBPDS Biotechnology CorporationLTM Mar 2026$791.06K +301.2%——
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$721K +149.2%—2.1%
Peer median (excluding PDSB) $938K-7.3%-32.1%1.9%

Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(16.92M)(40.85M)(42.94M)(37.61M)(34.5B)
Depreciation & Amortization5.36K8617.36K21.11K1.55B
Deferred Income Tax00000
Stock-Based Compensation4.11M5.2M7.61M6.85M4.11B
Change in Working Capital75.82K4.47M(199.28K)(5.75M)(382.97K)
Accounts Receivables00000
Inventory00000
Accounts Payables(105.82K)(90.12K)5.76M(5.3M)1.89M
Other Working Capital181.64K4.57M(5.96M)(453.77K)(2.27M)
Other Non-Cash Items241.03K5.47M1.87M1.46M1.08B
Operating Cash Flow(12.49M)(25.71M)(33.64M)(35.03M)(27.75B)
Capital Expenditures000(29K)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow000(29K)0
Debt Repayment025M(59.3K)(3.18M)(7.56M)
Common Stock Issued48.54M9.86M16.13M22.6M20.34M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities344.13K(568.87K)308.94K774.09K12.76B
Financing Cash Flow48.89M34.29M16.38M20.19M12.77B
Effect of Forex Changes00000
Net Change in Cash36.4M8.58M(17.26M)(14.87M)(14.98B)
Free Cash Flow(12.49M)(25.71M)(33.64M)(35.06M)(27.75B)

PDS Biotechnology Corporation

NASDAQ:PDSB

Intrinsic Alpha fair value

Locked

Current Price

$0.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.